RxDoctor Payments Data

Pradeep Ramulu, MD

Ophthalmology · Baltimore, MDNPI 1003821521

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $33,658 of the $38,977 with a category attached, or 86.4%. 10 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 48.1% of the total. Reporting peaked in 2022 at $10,456 and has fallen 96.4% since, to $379 in 2025. Among ophthalmology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$38,977in general payments, 2019–2025

Across 45 payments — averaging $866.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$19K
  • Alcon$9K
  • Janssen Research & Development, LLC$7K
  • Alcon Research LLC$3K
  • Ivantis, Inc$655
  • AbbVie$140
  • plus $292 from 4 others

What the payments were for

  • Consulting fees$33,65886%
  • Speaking & faculty fees$2,8507%
  • Travel & lodging$7862%
  • Food & beverage$1,6844%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,977 in reported general payments places this provider in the 90th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$477,375
Medicare patients
1,002
Services billed
3,743

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate59$34,759
LumiganBimatoprost54$30,595
CombiganBrimonidine Tartrate/Timolol18$10,740
Travoprost44$10,312
SimbrinzaBrinzolamide/Brimonidine Tart25$9,461
Brinzolamide32$8,436
Brimonidine Tartrate223$8,016
Latanoprost502$7,981
Travatan ZTravoprost13$7,558
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat316$7,502
Dorzolamide-TimololDorzolamide/Timolol/Pf28$5,802
TafluprostTafluprost/Pf22$5,680
VyzultaLatanoprostene Bunod11$5,667
Bromfenac Sodium11$5,567
Prednisolone Acetate106$5,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$140$46,06087 claims
AlconSimbrinza$9,456$9,46125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →